About the dataset

Primary description: Depression treatment prediction

The International Study to Predict Optimized Treatment for Depression (iSPOT-D) is a large, multi-center randomized clinical trial aimed to identify baseline predictors and moderators of treatment response for MDD. Outpatients (aged 18-65) with MDD were enrolled to escitalopram, sertraline, or venlafaxine. MDD participants and matched healthy controls underwent baseline assessment, cognitive testing, and some underwent imaging. An additional subset of individuals underwent a repeat of these assessments at week eight.

The study is part of the COORDINATE-MDD consortium. For more information, see: https://doi.org/10.1038/s44220-023-00187-w.
Study International Study to Predict Optimized Treatment in Depression
Study Website iSPOT-D
Data Descriptor Paper https://pubmed.ncbi.nlm.nih.gov/21208417/
DUA https://redcap.link/pmhw_analysis_request. If the link doesn't work, go to https://www.stanfordpmhw.com/datasets and search for "iSPOT-D"
Country/Region Australia
Disease Tag depression
Age (mean ± SD) 34.5 ± 12.2
Age Range 18-65
% Female 51.5
CUBIC Project /cbica/projects/MultisiteMD
PI for CUBIC Access Approval Christos Davatzikos
N Subjects 202
N MR Sessions 202
DLMUSE
(200/200 complete)
/cbica/projects/MultisiteMD/Pipelines/MultisiteMD_DLMUSE_2025/Stanford_iSPOTD/Results/Stanford_iSPOTD_DLMUSE_Volumes.csv
Non-Imaging Data

Contact Mathilde Antoniades to request access to the non-imaging data.

/cbica/home/harmang/for_others/final_combined_istaging_withMUSE.csv

Data consolidated and harmonized in 2026.

This study: subset with df[df.Study == 'i-SPOT-D']


Funding
iSPOT-D is sponsored by Brain Resource Company Operations Pty Ltd.